Model‐Based Meta‐Analysis of Objective Response Rate and Survival Endpoints to Compare PD ‐1 and PD ‐ L1 Treatment Outcomes in Non‐Small Cell Lung Cancer
Open Access
- 18 February 2026
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (3) , e70196
Abstract
Programmed cell death (PD) protein (ligand [L])‐1 inhibitors are established treatments for metastatic non‐small cell lung cancer (mNSCLC). In oncology, progression‐free survival (PFS) and objective response rate (ORR) are often used as surrogates for overall survival (OS) to inform clinical development; however, there remains uncertainty in the concordance between these endpoints. This study evaluated the impact of a broad set of PD‐(L)1 inhibitors on efficacy, explored the relationship between ORR and survival endpoints, and compared PD‐1 and PD‐L1 treatments for mNSCLC. A dataset of 114 studies was used to conduct a sequential two‐stage model‐based meta‐analysis (MBMA). Firstly, an MBMA with mixed‐effects logistic regression was applied to evaluate treatment‐specific and clinical covariate effects on ORR. Secondly, MBMAs for OS and PFS were conducted with a mixed‐effects semi‐parametric proportional hazard approach using digitized Kaplan–Meier curves, with the treatment type, covariates, and ORR as inputs. ORR was demonstrated to be a significant predictor of OS and PFS. Simulations of head‐to‐head comparisons of treatment types were conducted using these models. Trends in predicted outcomes numerically favored PD‐1 over PD‐L1 treatments, but differences were not statistically significant. These findings support evidence‐based decision‐making for late‐stage trial designs using ORR data from earlier phase trials, enabling benchmarking of emerging data by adjusting for explained and unexplained sources of variability in existing and emerging data.Keywords
This publication has 20 references indexed in Scilit:
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerJAMA Oncology, 2020
- The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapyCancer Biology & Medicine, 2019
- Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of biasActa Oncologica, 2019
- How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy2019
- Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trialsEuropean Journal of Cancer, 2019
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysisJournal of Cancer Research and Clinical Oncology, 2018
- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy TrialsClinical Cancer Research, 2018
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- MissForest—non-parametric missing value imputation for mixed-type dataBioinformatics, 2011